Latest From Chromocell Corp.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
This week's roundup includes high level appointments by Merck KGaA, Chromocell Corporation, Kymab and GW Pharmaceuticals, in addition to board appointments by Fortuna Fix and Motif Bio.
J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?
Biopharma executives discuss the value of innovative medicines in the eyes of patients and payers, but before that companies must determine how partners or acquirers would value their drug candidates.
J.P. Morgan Executive Roundtable, Part 3: Financing Is Difficult, But Available For Drugs That Provide Value
Plunging biopharma company stock values and declining IPO activity have contributed to a more difficult financing environment, but money is still available for public and private drug developers whose products provide value in the eyes of patients and payers.
- Drug Discovery Tools
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Chromocell Corp.
- Senior Management
Christian Kopfli, CEO
Ken Rowe, VP, Commercial Dev.
Marcus C Sands, VP, Corp. Dev.
Heikki Mansikka, MD, PhD, VP, Clinical Dev.
- Contact Info
Phone: (732) 565-1113
685 US Hwy. 1
North Brunswick, NJ 08902
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.